AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Combination shows consistent benefit across prespecified post-progression outcomes
Combination shows consistent benefit across prespecified post-progression outcomes
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
These re-agent and diagnostic test kits come with 99.7% accuracy
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Comprehensive clinical development programs being initiated for each investigational candidate
Subscribe To Our Newsletter & Stay Updated